Dr. H. Tarik Kani talks to Dr. Axel Dignass (Germany) about his recent publication about the impact of Ustekinumab on health-related quality of life in moderate-to-severe Crohn’s disease which was an open-label, multicenter, randomized study evaluated the quality of life prospectively in Crohn’s patients who treated with Ustekinumab.